...
首页> 外文期刊>Drug Design, Development and Therapy >Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model
【24h】

Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model

机译:铁(III)-橄榄石在卵巢癌动物模型中的凋亡和化学治疗性质

获取原文
           

摘要

Abstract: The cytotoxicity of organometallic compounds iron(III)-, cobalt(III)-, manganese(II)-, and copper(II)-salophene (-SP) on platinum-resistant ovarian cancer cell lines was compared. Fe-SP displayed selective cytotoxicity (IC50 at ~1 μM) against SKOV-3 and OVCAR-3 cell lines while Co-SP caused cytotoxic effects only at higher concentrations (IC50 at 60 μM) and Cu-SP effects were negligible. High cytotoxicity of Mn-SP (30–60 μM) appeared to be nonspecific because the Mn-chloride salt reduced cell viability similarly. The effect of Fe-SP at 1 μM proved to be ovarian cancer cell selective when compared to a panel of cell lines derived from different tumors. The first irreversible step in the induction of cell death by Fe-SP occurred after 3 hrs as indicated by the mitochondrial transmembrane potential (ΔΨm) and was mainly linked to apoptotic, not necrotic events. To evaluate the toxicity of Fe-SP in vivo we conducted an acute toxicity study in rats. The LD50 of Fe-SP is >2000 mg/kg orally and >5.5 mg/kg body weight by intraperitoneal injection. An ovarian cancer animal model showed that the chemotherapeutic relevant dose of Fe-SP in rats is 0.5–1 mg/kg body weight. The present report suggests that Fe-SP is a potential therapeutic drug to treat ovarian cancer.
机译:摘要:比较了有机金属化合物铁(III)-,钴(III)-,锰(II)-和铜(II)-橄榄石(-SP)对铂耐药性卵巢癌细胞系的细胞毒性。 Fe-SP对SKOV-3和OVCAR-3细胞系表现出选择性的细胞毒性(约1μM的IC50),而Co-SP仅在较高浓度(60μM的IC50)时才具有细胞毒性作用,而Cu-SP的作用可忽略不计。 Mn-SP(30–60μM)的高细胞毒性似乎是非特异性的,因为Mn-氯化物盐同样会降低细胞活力。与来自不同肿瘤的一组细胞系相比,Fe-SP在1μM的作用被证明是卵巢癌细胞选择性的。 Fe-SP诱导细胞死亡的第一个不可逆步骤发生在3小时后,如线粒体跨膜电位(ΔΨm)所示,这主要与凋亡而非坏死事件有关。为了评估Fe-SP在体内的毒性,我们在大鼠中进行了急性毒性研究。 Fe-SP的LD50口服> 2000 mg / kg,经腹膜内注射> 5.5 mg / kg体重。卵巢癌动物模型显示,Fe-SP在大鼠中的化学治疗相关剂量为0.5–1 mg / kg体重。本报告表明,Fe-SP是治疗卵巢癌的潜在治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号